News
UTHR
318.00
+1.60%
5.01
First Week of November 21st Options Trading For United Therapeutics (UTHR)
NASDAQ · 53m ago
Weekly Report: what happened at UTHR last week (0317-0321)?
Weekly Report · 7h ago
Buy Recommendation for United Therapeutics: Undervalued Potential in IPF Treatment with Tyvaso
TipRanks · 3d ago
2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off
Barchart · 6d ago
United Therapeutics Insiders Sell US$7.1m Of Stock, Possibly Signalling Caution
Simply Wall St · 03/17 10:08
Weekly Report: what happened at UTHR last week (0310-0314)?
Weekly Report · 03/17 09:14
2 Value Stocks on Our Watchlist and 1 to Ignore
Barchart · 03/12 14:52
Tracking Renaissance Technologies 13F Portfolio - Q4 2024 Update
Seeking Alpha · 03/12 01:29
Positive Outlook for United Therapeutics Amidst Competitive Landscape and Growth Initiatives
TipRanks · 03/10 12:15
Weekly Report: what happened at UTHR last week (0303-0307)?
Weekly Report · 03/10 09:15
United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025
Barchart · 03/04 06:00
Top Executives Cash In on United Therapeutics Stock!
TipRanks · 03/04 02:10
Weekly Report: what happened at UTHR last week (0224-0228)?
Weekly Report · 03/03 09:14
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Beam Therapeutics (BEAM)
TipRanks · 02/28 14:50
United Therapeutics Corp. Reports Record Revenue and Growth
TipRanks · 02/28 00:22
United Therapeutics price target lowered to $420 from $430 at Leerink
TipRanks · 02/27 16:35
UNITED THERAPEUTICS CORP <UTHR.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $420 FROM $430
Reuters · 02/27 15:35
MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question
Seeking Alpha · 02/27 15:32
United Therapeutics price target lowered to $346 from $354 at Morgan Stanley
TipRanks · 02/27 14:25
Strong Buy Rating for United Therapeutics Driven by Robust Growth and Promising Pipeline
TipRanks · 02/27 14:15
More
Webull provides a variety of real-time UTHR stock news. You can receive the latest news about United Therapeutics Corp. through multiple platforms. This information may help you make smarter investment decisions.
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.